RWA Wealth Partners LLC Acquires 2,461 Shares of Cencora, Inc. $COR

RWA Wealth Partners LLC boosted its stake in shares of Cencora, Inc. (NYSE:COR) by 7.0% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 37,625 shares of the company’s stock after buying an additional 2,461 shares during the quarter. RWA Wealth Partners LLC’s holdings in Cencora were worth $11,759,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Vermillion & White Wealth Management Group LLC grew its position in shares of Cencora by 69.4% during the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock valued at $31,000 after acquiring an additional 43 shares during the period. Cloud Capital Management LLC bought a new stake in shares of Cencora in the 3rd quarter worth approximately $31,000. Westside Investment Management Inc. lifted its stake in Cencora by 200.0% in the third quarter. Westside Investment Management Inc. now owns 105 shares of the company’s stock valued at $33,000 after purchasing an additional 70 shares during the last quarter. Copia Wealth Management grew its holdings in Cencora by 505.0% during the third quarter. Copia Wealth Management now owns 121 shares of the company’s stock valued at $38,000 after purchasing an additional 101 shares during the period. Finally, Caldwell Trust Co purchased a new stake in Cencora in the second quarter worth $46,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Analyst Upgrades and Downgrades

COR has been the topic of several recent analyst reports. Evercore lowered their price target on Cencora from $440.00 to $420.00 and set an “outperform” rating on the stock in a report on Thursday, February 5th. Bank of America decreased their price objective on Cencora from $380.00 to $360.00 and set a “neutral” rating on the stock in a report on Monday, January 5th. Weiss Ratings raised Cencora from a “hold (c+)” rating to a “buy (b)” rating in a research note on Thursday, February 5th. JPMorgan Chase & Co. boosted their price target on shares of Cencora from $417.00 to $419.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 10th. Finally, Mizuho increased their price target on shares of Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a research report on Thursday, November 6th. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $399.00.

Insiders Place Their Bets

In other news, CEO Robert P. Mauch sold 5,096 shares of the firm’s stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $354.73, for a total transaction of $1,807,704.08. Following the sale, the chief executive officer directly owned 66,726 shares in the company, valued at $23,669,713.98. This trade represents a 7.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Silvana Battaglia sold 1,677 shares of the business’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $345.00, for a total value of $578,565.00. Following the completion of the transaction, the executive vice president directly owned 18,796 shares in the company, valued at approximately $6,484,620. This represents a 8.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 15,220 shares of company stock worth $5,282,867. Company insiders own 0.38% of the company’s stock.

Cencora Stock Down 0.3%

Shares of Cencora stock opened at $364.80 on Wednesday. The company has a 50-day simple moving average of $350.19 and a two-hundred day simple moving average of $332.57. The stock has a market capitalization of $70.96 billion, a PE ratio of 43.85, a price-to-earnings-growth ratio of 1.71 and a beta of 0.68. Cencora, Inc. has a 52-week low of $244.97 and a 52-week high of $377.54. The company has a debt-to-equity ratio of 3.62, a quick ratio of 0.51 and a current ratio of 0.92.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.04 by $0.04. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The firm had revenue of $85.93 billion for the quarter, compared to the consensus estimate of $86.12 billion. During the same quarter last year, the firm posted $3.73 EPS. The business’s quarterly revenue was up 5.5% compared to the same quarter last year. On average, analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, March 2nd. Investors of record on Friday, February 13th will be given a dividend of $0.60 per share. The ex-dividend date is Friday, February 13th. This represents a $2.40 annualized dividend and a yield of 0.7%. Cencora’s payout ratio is 28.85%.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.